Amneal Pharmaceuticals (AMRX) PEG Ratio: History & Chart

Amneal Pharmaceuticals, Inc.(AMRX)

Drug Manufacturers - Specialty & Generic · Bridgewater, NJ

$20.35+0.05 (+0.25%)

Delayed quote: Oct 5, 2026, 4:00 PM EDT

About Amneal Pharmaceuticals, Inc.

Amneal Pharmaceuticals, Inc., operating alongside its various subsidiaries, is a diversified pharmaceutical company involved in the development, acquisition of licenses, manufacturing, marketing, and distribution of both generic and specialized medicinal products. These offerings span a multitude of delivery formats and target a wide range of therapeutic needs. Its operations are structured into three distinct divisions: Generics, Specialty, and AvKARE. The Generics division is responsible for creating, producing, and bringing to market a diverse portfolio of complex pharmaceutical formulations. This includes oral solid doses, injectable solutions, ophthalmic preparations, liquid medications, topical applications, softgels, inhalants, and transdermal patches, all catering to a broad spectrum of medical needs. Within the Specialty division, the company concentrates on the advancement, marketing, sales, and distribution of proprietary branded pharmaceuticals. Key therapeutic areas for this segment include neurological conditions, endocrine disorders, and parasitic ailments, among others. Notable offerings include Emverm, a chewable tablet prescribed for single or mixed parasitic infections such as pinworm and various hookworms; Rytary, designed for the management of Parkinson's disease; and Unithroid, used in treating hypothyroidism. The AvKARE segment primarily serves governmental entities, particularly the Department of Defense and the Department of Veterans Affairs, supplying them with pharmaceuticals, medical and surgical supplies, and related services. Additionally, this segment engages in the bulk distribution of bottled and unit-dose pharmaceuticals under its AvKARE and AvPAK brands, alongside medical and surgical items. It also manages the packaging and large-scale distribution of medications and nutritional supplements for its retail and institutional clientele. Products from Amneal reach consumers through a network comprising wholesale suppliers, third-party distributors, hospitals, large pharmacy chains, and independent drugstores. Its operational footprint extends across the United States, India, Ireland, and other international markets. Established in 2002, the company was initially incorporated as Atlas Holdings, Inc., before adopting the name Amneal Pharmaceuticals, Inc. in 2018. Its corporate headquarters are situated in Bridgewater, New Jersey.

Bridgewater, NJ

8,700 employees

www.amneal.com

Healthcare / Drug Manufacturers - Specialty & Generic

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
CEO: Chirag K. Patel

View full financials

NAME	MARKET CAP	PEG RATIO	TTM	3Y	5Y
Amneal Pharmaceuticals, Inc. (AMRX)	$6.50B	N/A	N/A	N/A	N/A
GRAIL Inc. (GRAL)vs ›	$6.61B	N/A	N/A	N/A	N/A
Hims & Hers Health, Inc. (HIMS)vs ›	$6.62B	N/A	N/A	N/A	N/A
Iovance Biotherapeutics, Inc. (IOVA)vs ›	$6.32B	N/A	N/A	N/A	N/A
Chemed Corporation (CHE)vs ›	$6.68B	N/A	2.98	2.74	2.10
Immunovant, Inc. (IMVT)vs ›	$6.86B	N/A	N/A	N/A	N/A
CG Oncology Inc. (CGON)vs ›	$6.06B	N/A	N/A	N/A	N/A
Alkermes plc (ALKS)vs ›	$7.17B	N/A	N/A	N/A	N/A
Ionis Pharmaceuticals, Inc. (IONS)vs ›	$7.23B	N/A	N/A	N/A	N/A
CRISPR Therapeutics AG (CRSP)vs ›	$5.53B	N/A	N/A	N/A	N/A

NAME

MARKET CAP

PEG RATIO

TTM

Amneal Pharmaceuticals, Inc. (AMRX)

$6.50B

N/A

GRAIL Inc. (GRAL)vs ›

$6.61B

N/A

Hims & Hers Health, Inc. (HIMS)vs ›

$6.62B

N/A

Iovance Biotherapeutics, Inc. (IOVA)vs ›

$6.32B

N/A

Chemed Corporation (CHE)vs ›

$6.68B

N/A

2.98

2.74

2.10

Immunovant, Inc. (IMVT)vs ›

$6.86B

N/A

CG Oncology Inc. (CGON)vs ›

$6.06B

N/A

Alkermes plc (ALKS)vs ›

$7.17B

N/A

Ionis Pharmaceuticals, Inc. (IONS)vs ›

$7.23B

N/A

CRISPR Therapeutics AG (CRSP)vs ›

$5.53B

N/A

PEG Ratio Formula & Definition

PEG Ratio = P/E Ratio / 5-Year Diluted EPS CAGR (%)

The PEG ratio divides the price-to-earnings ratio by the company's five-year compound annual growth rate of diluted EPS, expressed in percent. A P/E of 20 and a five-year diluted EPS CAGR of 10% give a PEG of 2.0. The growth is reported, historical earnings growth from annual statements, not an analyst forecast. A PEG near 1 is often read as fairly priced for its growth; lower can mean cheaper relative to growth. The ratio is N/A when the P/E is unavailable or not positive, or when the five-year diluted EPS CAGR is unavailable or not positive. Each day of the history uses the CAGR that was known on that day.

PEG Ratio: N/A

AMRX PEG Ratio Metrics

AMRX Competitors' PEG Ratio

Growth-Adjusted Valuation

PEG Ratio Formula & Definition

Related Metrics